- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00607022
A Randomized Prospective Clinical Trial Comparing Single Tooth Implant 3 Loading Protocols
the Effects of 3 Loading Protocols on Dental Implant Stability in Healed Ridges
Study Overview
Detailed Description
MATERIALS AND METHODS This longitudinal human clinical trial is designed as a prospective study, to measure implant stability with the resonance frequency analyzer (Osstell, Integration Diagnostics AB, Sweden) at time of implant placement and up to 16 weeks post placement. After 16 weeks, a definitive implant abutment will be placed and a final dental crown delivered. No further follow-up will be done with the resonance frequency approach. However, all subjects will be followed through 3 years post implant placement as described for each follow-up visit. The study population consists of subjects at the University of Iowa's College of Dentistry. Subjects presenting with one tooth missing in the anterior (incisor/canine) or pre-molar regions of the mandible or maxilla with existing teeth that were healthy or adequately restored shall be screened based on the inclusion/exclusion criteria. The missing tooth is to be replaced with a fixed implant restoration on one implant.
SEQUENCE OF VISITS A. Visit 1: Screening Examination
Subjects shall be seen for evaluation and for collection of baseline data. Pre-treatment data shall be recorded on case report forms. The visit shall include:
- Explanation to the patient of the purposes of the study and the planned procedures related to the study.
- Explanation to the subject of the risks and possible complications of participation in the study. Patients shall be notified that inclusion in the study is for the purpose of providing implant treatment only and that no provision for other active treatments are guaranteed or implied except for care related to the implant aspect of their oral cavity. This treatment shall be agreed upon as outlined for their specific case.
Implant Site Selection: Adequate bone volume is needed to accommodate the planned endosseous dental implant. This will mean sufficient height such that the implant would not encroach on vital structures (such as inferior alveolar nerve), and sufficient width that the implant could be placed within the confines of the existing bone without dehiscence or fenestration, requiring significant grafting at time of implant placement. Typically, this will mean space dimensions will be: 6 mm or greater ridge width facial-lingual and > 6 mm in the mesial to distal dimension . If the implant can be placed and only a few screw threads are exposed, grafting is allowed to cover these threads. In the planned occlusal-gingival dimension, there must be at least 7 mm of space from the planned head of the implant to the planned occlusal plane.
The subject should be notified that inclusion in the study is conditional upon satisfying the inclusion and exclusion criteria as seen in Table 1. Only subjects satisfying the Inclusion/Exclusion criteria shall be enrolled.
The dental implant system to be used is the Astra Tech OsseoSpeed Dental Implant System (Astra Tech AB, Mölndal Sweden). This is an FDA cleared product under FDA 510k clearance act (FDA clearance 4/30/2004). This protocol calls for use of only the 4.0 mm diameter by 11 mm long dental implant (OsseoSpeed Aqua platform; Ref Number 24622; Astra Tech AB) in the anterior (incisor/canine) or posterior pre-molar regions of the mandible or maxilla. All sites must have sound natural or restored teeth/implants Mesial and Distal to the planned site of interest (Bounded Edentulous Space or BES). The patient should otherwise have a restored stable occlusion that is mutually protected. No implants will be placed in molar sites. The implant lengths accepted in the study are 11 mm. Clinical and radiographic screening will be used to limit the study to patients with sufficient bone quantity to completely encase the implant.
Upon review of the subject's health history, inclusion/exclusion criteria a screening clinical assessment will be made. Existing dental radiographs within the past 6 months shall be acceptable. No new radiographs will be made until subject enrollment and obtaining signed informed consent. The subject will be given an informed consent for the study and reviewed with the clinical study coordinator. Preliminary diagnostic impressions will made (Penta, 3M ESPE) and poured in dental stone (Whip Mix Corp., Louisville, KY). Implant subjects may have a pre-operative Cone Bean CT imaging study (Galileos; Sirona, Charlotte NC; www.sirona.com) made at the College of Dentistry's Department of Oral Maxillofacial Radiology at the discretion of the Principal Investigator following diagnostic work-up. Subjects shall be either patients of record of the College of Dentistry or shall be enrolled if new to the College. Patient records are electronic (WinDent) along with a paper version. Paper-based Case Report Forms (CRF) containing subject's medical information will be kept in one central file in a locked cabinet in the Dental Clinical Research Center. This data will be kept in a secured file accessible only by the PI and the Clinical Coordinator.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- The University of Iowa College of Dentistry
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The patient is 18 years or older.
- Ability to understand and sign the informed consent prior to starting the study.
- Ability and willingness to comply with all study requirements.
- Adequate oral hygiene (defined as an average Modified Sulcus Bleeding Index of 1 or less and an average Modified Plaque Index of 1 or less).
- Must be a bounded edentulous space.
- Adequate bone volume to accommodate the planned endosseous dental implant (e.g. sufficient height such that the implant would not encroach on vital structures such as inferior alveolar nerve, and sufficient width that the implant could be placed within the confines of the existing bone without dehiscence or fenestration, requiring significant grafting at time of implant placement). The only implant utilized in this protocol will be a 4.0 mm diameter by 11 mm long implant (Fixture OsseoSpeed Astra Tech).
Typically, this will mean space dimensions will be: 6 mm or greater ridge width facial-lingual and > 6 mm in the mesial to distal dimension . If the implant can be placed and only a few screw threads are exposed, grafting is allowed to cover these threads. In the planned occlusal-gingival dimension, there must be at least 7 mm of space from the planned head of the implant to the planned occlusal plane.
- Osteotome use will be allowed but there must be a minimum of 8mm of bone height from the alveolar crest to the floor of the sinus. Maximum sinus lift will be 4 mm.
- Existing teeth are healthy and adequately restored, and desired a fixed restoration on implants.
- Patient has a mutually protected occlusion.
- The patient, if of childbearing potential, had a negative pregnancy test within one week prior to surgery.
Exclusion Criteria:
- Patients who have smoked cigarettes or chewed tobacco within the past year.
- History of alcoholism or drug abuse within the past 5 years. - Severe bruxing or clenching habits
- Untreated periodontitis
- Patients at undue risk for an outpatient surgical procedure
- Presence of residual roots at the implant site- Patients with history of site development (extensive bone augmentation) at the implant site in the past 4 months.
- Placement of implant in an extraction site that had been healing for less than 2 month.
- Presence of local inflammation or mucosal diseases such as lichen planus.
- Uncontrolled diabetes (defined as HA1c > 7.0 percent).
- Current hematologic disorder or chronic use of coumarin (or similar) anti-coagulant therapies.
- History of leukocyte dysfunction and deficiencies
- Metabolic bone disorders
- History of renal failure
- History of liver disease
- Immunocompromised patients having HIV, RA, SLE or other collagen vascular disorders.
- Chronic corticosteroid use.
- Current chemotherapy
- History of use of IV-based bisphosphonates.
- History of radiation treatment to the head or neck
- Patients requiring grafting of bone or mucosal tissue at the time of implant placement which would require submersion of the implant during the healing period.
- Use of any investigational drug or device within the 30 day period immediately prior to implant surgery
- Patients requiring submersion of implants for esthetic reasons.
- Patient requiring ongoing dental treatment in the same quadrant or opposing quadrant during the initial 16 week healing period.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: immediate load
immediate load of dental implant based on the bone quality determined by the insertion torque value
|
Dental implant stability measured with the resonance frequency analyzer (Osstell, Integration Diagnostics AB, Sweden) at time of implant placement and up to 16 weeks post placement.
|
|
ACTIVE_COMPARATOR: Loading at 6 weeks
delayed load (6 weeks post surgery) of dental implants based on bone quality determined by the insertion torque value
|
Dental implant stability measured with the resonance frequency analyzer (Osstell, Integration Diagnostics AB, Sweden) at time of implant placement and up to 16 weeks post placement.
|
|
ACTIVE_COMPARATOR: Loading at 12 weeks
traditional loading of dental implants (12 weeks post surgery) based on bone quality determined by the insertin torque value.
|
Dental implant stability measured with the resonance frequency analyzer (Osstell, Integration Diagnostics AB, Sweden) at time of implant placement and up to 16 weeks post placement.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Implant Stability Scale (ISQ) Score Change After 16 Weeks
Time Frame: 16 weeks
|
The objective of this study is to examine the change in implant stability upon three different loading regimens during the first sixteen weeks following implant placement.
ISQ score (1-100), where higher score equals more stability, was assessed.
The main hypotheses of the study are 1) Implant stability (ISQ) is minimally affected when physiologic load is applied to an implant during the healing process.
|
16 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 200710722
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.